本文選題：精神分裂癥 + 激越��； 參考：《中國新藥與臨床雜志》2017年01期

【摘要】：目的探討齊拉西酮注射液治療精神分裂癥激越癥狀后序貫至齊拉西酮口服藥物的療效與安全性。方法將122例經(jīng)齊拉西酮注射液治療有效的精神分裂癥興奮激越癥狀患者按臨床決策自然分為口服齊拉西酮組(62例)與口服利培酮/奧氮平組(60例)。以陽性與陰性癥狀量表(PANSS)減分率評定療效,以社會功能缺陷篩查量表(SDSS)評定社會功能,以監(jiān)測心電圖、催乳素、血糖、血脂變化及副反應量表(TESS)評定不良反應。結果齊拉西酮注射液治療72 h后PANSS興奮因子評分明顯下降(P0.01);序貫至口服用藥后,口服齊拉西酮組與口服利培酮/奧氮平組在臨床治愈率、有效率、PANSS量表評分及SDSS量表評分方面無顯著差異(均P0.05),但口服齊拉西酮組月經(jīng)紊亂(催乳素升高)、體重增加、血脂代謝異常及血糖升高、錐體外系反應等不良反應發(fā)生率明顯低于口服利培酮/奧氮平組(均P0.05)�？诜R拉西酮服藥依從性更好,治療8個月后中斷率更低(P0.05);生存分析也表明兩組治療中斷率有顯著差異(P0.05)。結論齊拉西酮注射液治療精神分裂癥激越癥狀后序貫至口服齊拉西酮后長期療效好,且不良反應少、依從性好、治療中斷率低,更利于維持期的治療。
[Abstract]:Objective to investigate the efficacy and safety of ziprasidone injection in the treatment of schizophrenic agitation symptoms after sequential ziprasidone oral administration. Methods 122 patients with excitatory agitation symptom treated by ziprasidone injection were divided into two groups according to clinical decision: 62 cases of oral ziprasidone group and 60 cases of oral risperidone / olanzapine group. The efficacy was assessed with the positive and negative symptom scale (PANSS), the social function was assessed with the social function screening scale (SDSS), and the adverse reactions were assessed by ECG, prolactin, blood glucose, blood lipid and side effects. Results the score of PANSS excitatory factor of ziprasidone injection decreased significantly 72 hours after treatment, and the clinical cure rate of Ziprasidone group and risperidone / olanzapine group was significantly lower than that of oral ziprasidone group after oral administration of ziprasidone and risperidone / olanzapine. There was no significant difference in the effective rate of PANSS scale and SDSS scale (all P 0.05), but the menstrual disorder (prolactin increased, weight gain, dyslipidemia and blood sugar increased) in the oral ziprasidone group. The incidence of adverse reactions such as extrapyramidal reaction was significantly lower than that in risperidone / olanzapine group (all P 0.05). Oral ziprasidone had better compliance, and the interruption rate was lower after 8 months of treatment, and survival analysis showed that there was a significant difference between the two groups in the treatment interruption rate. Conclusion Ziprasidone injection has good long-term curative effect after sequential treatment of schizophrenia agitation symptom and oral ziprasidone, with less adverse reactions, good compliance, low treatment interruption rate, and is more favorable for the treatment of maintenance period.
【作者單位】： 天津市安定醫(yī)院心境障礙科;
【分類號】：R749.3

【參考文獻】

相關期刊論文 前7條

1 褚文浩;吳志鵬;;齊拉西酮與奧氮平治療精神分裂癥的臨床療效及安全性比較[J];中國現(xiàn)代醫(yī)生;2014年13期

2 秦玲;袁天懿;姚明榮;岳偉清;滕林;;齊拉西酮與利培酮治療精神分裂癥陰性癥狀療效的對照研究[J];臨床精神醫(yī)學雜志;2011年05期

3 王冬梅;;奧氮平與齊拉西酮對精神分裂癥患者生活質(zhì)量影響的對照研究[J];臨床精神醫(yī)學雜志;2011年05期

4 黃繼忠;江開達;司天梅;賈福軍;梅其一;郝偉;李凌江;趙靖平;王剛;;齊拉西酮治療精神分裂癥臨床應用指導建議[J];中國新藥與臨床雜志;2011年09期

5 李學靈;鄒振民;劉秀麗;柳宏宇;;齊拉西酮與利培酮治療精神分裂癥對照研究[J];臨床精神醫(yī)學雜志;2010年03期

6 劉忠;王立娟;李麗;;奎硫平及齊拉西酮對心電圖QTc影響的研究[J];中國健康心理學雜志;2009年11期

7 李樂華;趙靖平;許秀峰;蒙華慶;寧潔;;國產(chǎn)齊拉西酮與氟哌啶醇注射液治療精神分裂癥急性激越癥狀的對照研究[J];中華精神科雜志;2006年04期

【共引文獻】

相關期刊論文 前10條

1 徐棟麗;韓冰;;口服鹽酸齊拉西酮致血壓升高1例[J];藥物流行病學雜志;2017年02期

2 賈峰;王立娜;王U，

本文編號：1908163